A61K 38/179
For growth factors
Official title: {for growth factors; for growth regulators}
A61K38/179 (For growth factors) appears on 564 US grants and 1,131 published applications in this corpus.
Search patents in A61K- Granted patents
- 564
- Published applications
- 1,131
- Assignees
- 464
- Inventors
- 1,631
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 4 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 10 |
| 2003 | 1 | 10 |
| 2004 | 1 | 18 |
| 2005 | 2 | 14 |
| 2006 | 0 | 18 |
| 2007 | 5 | 21 |
| 2008 | 8 | 24 |
| 2009 | 7 | 25 |
| 2010 | 14 | 25 |
| 2011 | 11 | 21 |
| 2012 | 14 | 38 |
| 2013 | 20 | 38 |
| 2014 | 26 | 53 |
| 2015 | 26 | 45 |
| 2016 | 31 | 60 |
| 2017 | 36 | 60 |
| 2018 | 27 | 75 |
| 2019 | 37 | 51 |
| 2020 | 42 | 77 |
| 2021 | 52 | 96 |
| 2022 | 47 | 96 |
| 2023 | 36 | 75 |
| 2024 | 34 | 72 |
| 2025 | 47 | 64 |
| 2026 | 32 | 44 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Pharmaceutical composition for treatment or prevention of ischemic cardiovascular disease29 Sep 2026US 12,746,220 B2Industry-Academic Cooperation Foundation, Yonsei University
- Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof11 Aug 2026US 12,703,742 B2
- Somatostatin receptor-based cancer therapy28 Jul 2026US 12,691,179 B2Vikas Kundra
- Methods for treating pulmonary disease with a ligand binding domain of a TGF-β type II receptor14 Jul 2026US 12,678,483 B2Acceleron Pharma Inc.
- Methods for treating osteoarthritis7 Jul 2026US 12,673,089 B2President and Fellows of Harvard College
- Micronized compositions for wound healing prepared from human umbilical cord tissue and intact amnion-chorion tissue having an intact intermediate spongy layer positioned there between1 Oct 2026US 2026/0294982 A1Biostem Technologies, Inc.
- Use of oncolytic viruses for the treatment of cancer24 Sep 2026US 2026/0286393 A1Amgen Inc.
- Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies10 Sep 2026US 2026/0263622 A1
- Reducing partial block programming using dynamic trim settings10 Sep 2026US 2026/0268999 A1Micron Technology, Inc.
- Compositions comprising pedf-derived short peptides for the treatment of neurotrophic keratitis diseases3 Sep 2026US 2026/0256881 A1BRIM Biotechnology, Inc.
Most cited
By later US patents
- ActRII receptor polypeptides, methods and compositions121US 7,709,605 B2Acceleron Pharma Inc. · 2010
- VEGF antagonist formulations for intravitreal administration112US 8,092,803 B2Regeneron Pharmaceuticals, Inc. · 2012
- Use of VEGF inhibitors for treatment of eye disorders106US 7,306,799 B2Regeneron Pharmaceuticals, Inc. · 2007
- Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth97US 7,612,041 B2Acceleron Pharma Inc. · 2009
- In vivo genetic modification of growth factor-responsive neural precursor cells96US 6,071,889 ANeurospheres Holdings Ltd. · 2000